Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Total Non-Current Liabilities (2016 - 2025)

Capricor Therapeutics (CAPR) has 14 years of Total Non-Current Liabilities data on record, last reported at $14.4 million in Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities rose 242.49% year-over-year to $14.4 million; the TTM value through Sep 2025 reached $14.4 million, up 242.49%, while the annual FY2024 figure was $4.0 million, 17.9% down from the prior year.
  • Total Non-Current Liabilities reached $14.4 million in Q3 2025 per CAPR's latest filing, up from $194603.0 in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $26.0 million in Q1 2022 and bottomed at $194603.0 in Q2 2025.
  • Average Total Non-Current Liabilities over 5 years is $8.3 million, with a median of $4.9 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: soared 660.79% in 2022, then crashed 95.6% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $5.8 million in 2021, then soared by 152.57% to $14.7 million in 2022, then plummeted by 66.97% to $4.9 million in 2023, then decreased by 17.9% to $4.0 million in 2024, then surged by 261.24% to $14.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $14.4 million in Q3 2025, $194603.0 in Q2 2025, and $3.8 million in Q1 2025.